Written by Ron Shamgar The Ozempic moment for SaaS refers to a pivotal disruption scenario where a transformative technology threatens to erode or fundamentally reshape an established market leader's core business model, much like the hype around Ozempic (and other...
In the rapidly evolving world of medical cannabis, one Australian company is quietly positioning itself as a potential industry leader. Bioxyne (BXN.ASX), a relatively young public company, is rewriting the playbook for medical cannabis manufacturing through a...
In an environment dominated by uncertainty, volatility, and shifting macro narratives, long-term investors must look beyond the noise to find quality businesses with structural tailwinds and undervalued potential. TAMIM Asset Management has long held the view that...
